Merck & Co., Inc., known as Merck Sharp & Dohme (MSD) outside the United States and Canada, is a global healthcare company that focuses on the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company is primarily engaged in the development of prescription medicines, vaccines, biologic therapies, and animal health products. Notable products include the cancer medication Keytruda, the vaccine Gardasil for HPV, and various treatments for conditions such as diabetes, cardiovascular diseases, and infectious diseases.
As a large-cap company, Merck holds a significant position in the pharmaceutical industry, competing with other major players like Pfizer, Johnson & Johnson, and Novartis. The company's strong portfolio of innovative drugs and vaccines has established it as a leader in several therapeutic areas. Merck's commitment to research and development is reflected in its substantial investment in clinical trials and new product pipelines, positioning it favorably in the competitive landscape.
Merck is recognized as a dividend-paying stock, appealing to income-focused investors. The company's financial stability is underscored by consistent revenue growth and a robust balance sheet. Recently, Merck has been focusing on expanding its oncology portfolio and enhancing its vaccine offerings, particularly in response to emerging health challenges. This strategic direction aims to leverage its research capabilities to address unmet medical needs and drive future growth.